​

SpringWorks Therapeutics (SWTX) Revenue & Revenue Breakdown

OverviewForecastFinancialsChartTranscripts

SpringWorks Therapeutics Revenue Highlights

Latest Revenue (Y)

$5.45M

Latest Revenue (Q)

$59.73M

SpringWorks Therapeutics Revenue by Period

SpringWorks Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$5.45M-11.39%
2022-12-31$6.15M100.00%
2021-12-31--100.00%
2020-12-31$35.00M100.00%
2019-12-31-100.00%
2018-12-31--

SpringWorks Therapeutics generated $5.45M in revenue during NA 2023, up -11.39% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

SpringWorks Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$59.73M184.36%
2024-03-31$21.01M285.64%
2023-12-31$5.45M-2.49%
2023-09-30$5.59M-4.15%
2023-06-30$5.83M4.88%
2023-03-31$5.56M-4.17%
2022-12-31$5.80M592.00%
2022-09-30$838.00K140.80%
2022-06-30$348.00K6860.00%
2022-03-31$5.00K100.00%
2021-12-31--100.00%
2021-09-30$121.00K-28.82%
2021-06-30$170.00K-26.09%
2021-03-31$230.00K-99.34%
2020-12-31$35.00M100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

SpringWorks Therapeutics generated $59.73M in revenue during Q2 2024, up 184.36% compared to the previous quarter, and up 1074.91% compared to the same period a year ago.

SpringWorks Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
APLSApellis Pharmaceuticals$366.28M$176.57M
BPMCBlueprint Medicines$249.38M$128.18M
KYMRKymera Therapeutics$78.59M$3.74M
ARVNArvinas$78.50M$102.40M
RLAYRelay Therapeutics$25.55M-
RVMDRevolution Medicines$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
STOKStoke Therapeutics$8.78M$4.89M
SWTXSpringWorks Therapeutics$5.45M$59.73M
PLRXPliant Therapeutics$1.58M-
BDTXBlack Diamond Therapeutics--
DAWNDay One Biopharmaceuticals-$20.07M
PASGPassage Bio--
TERNTerns Pharmaceuticals--
SANASana Bio--
GLUEMonte Rosa Therapeutics-$4.70M

SWTX Revenue FAQ

What is SpringWorks Therapeutics’s yearly revenue?

SpringWorks Therapeutics's yearly revenue for 2023 was $5.45M, representing a decrease of -11.39% compared to 2022. The company's yearly revenue for 2022 was $6.15M, representing an increase of 100.00% compared to 2021. SWTX's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.

What is SpringWorks Therapeutics’s quarterly revenue?

SpringWorks Therapeutics's quarterly revenue for Q2 2024 was $59.73M, a 184.36% increase from the previous quarter (Q1 2024), and a 924.93% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $21.01M, a 285.64% increase from the previous quarter (Q4 2023), and a 278.01% increase year-over-year (Q1 2023). SWTX's quarterly revenue for Q4 2023 was $5.45M, a -2.49% decrease from the previous quarter (Q3 2023), and a -6.07% decrease year-over-year (Q4 2022).

What is SpringWorks Therapeutics’s revenue growth rate?

SpringWorks Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.